Accolade — Q3 2022 Earnings Presentation
19 slides from Accolade's earnings presentation, Jan 10, 2022
Slide 1: Fiscal Third Quarter Earnings Presentation
Accolade (ACCD) Fiscal Third Quarter Earnings Presentation January 10, 2022
Slide 2: Forward-Looking Statements
This presentation contains “forward-looking statements” –that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such ‘‘anticipate,’’ ‘‘b
Slide 3: Rajeev Singh, Chief Executive Officer
Rajeev Singh Chief Executive Officer 3
Slide 4: 2021: A year of transformation
2021: A year of transformation Members Customers $200+ billion TAM 10+M 600+ $170BN Primary Care $22BN 2.1M 112 Expert Medical Opinion $24BN January December January December Advocacy 4
Slide 5: A Powerful, Personalized Healthcare Platform
A Powerful, Personalized Healthcare Platform Personal | Data Driven | Value Based Accolade Accolade Accolade Accolade Advocacy Expert MD Care One Personalized, trusted Real-time expert Same-day access to Value-based care that guidance and education consultations for virtual primary and deeply integr
Slide 6: Fiscal Year '23 Preview
Fiscal Year ‘23 Revenue vs Preview Adjusted EBITDA (Loss) as a % of Revenue* ($ in millions) 25% § Accolade One and Accolade Care $306 – Growth* first go-lives on 1/1 $309* § Expansion in customers, members, 170 133 77 95 partners, health plans § 25% revenue growth and reduction in Adjusted EBITDA l
Slide 7: Accolade ©2021 - Confidential
Accolade ©2021 - Confidential 7
Slide 8: Steve Barnes, Chief Financial Officer
Steve Barnes Chief Financial Officer 8
Slide 9: Fiscal Third Quarter 2022
Fiscal Third Quarter 2022 Results versus Guidance and Prior Year Actuals Guidance Prior Year YoY Revenue (reported) $83.5mm $74.5mm - $76.5mm $38.4mm 117% Revenue (pro forma)* $83.5mm $57.9mm 44% Adjusted EBITDA (Loss)** $(11.9)mm $(21.5)mm - $(24.5)mm $(11.4)mm (5)% Highlights § FQ3 revenue outperf
Slide 10: Fiscal Fourth Quarter and FY22 Guidance
Fiscal Fourth Quarter and FY22 Guidance Q4 FY 22 YoY Change FY 22 YoY Change (midpoint) (midpoint) Revenue $90mm - $93mm 54% $306mm - $309mm 81% Revenue (pro forma*) $90mm - $93mm 13% 30% $(48)mm - $(52)mm Adjusted EBITDA (Loss)** $(4)mm - $(8)mm (319)% (86)% (16% - 17%) Notes § Approximately $8mm o
Slide 11: Preliminary Guidance & Metrics
FY 2023 Preliminary Guidance & Metrics 25% § ACV at end of FY21 was $248m on a pro forma basis to include 2nd.MD (excluding case rate revenue) Revenue Growth § Tracking to add $50mm - $60mm of new annual recurring revenue for FY22 § Modifying ACV definition to reflect changes in Accolade business wi
Slide 12: Revenue and Customer Growth + Unit Economics Drive Path to Profitability
Revenue and Customer Growth + Unit Economics Drive Path to Profitability Revenue vs Adjusted EBITDA (Loss) as a % of Revenue* ($ in millions) * 25% annual revenue growth ~$600 $306 - $309* 95 133 170 77 Breakeven -6% -11% -16% -16% -25% -41% -56% FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 *Adjusted EBI
Slide 13: New Capabilities Improve Unit Economics
New Capabilities Improve Unit Economics Advocacy EMO + VPC Visit Fees Ecosystem Value-Based Shared Savings Incremental gross margin contribution higher Shared Savings on new solutions than Advocacy PEPM Opportunity Ecosystem ~$20 PEPM Virtual Primary Care & EMO: (based on $/visit or case utilization
Slide 14: Financial Targets and Goals (Non-GAAP)
Financial Targets and Goals (Non-GAAP) Long-Term Goals Commentary Adj. Gross Margin 50-55% Investments in technology and offering mix projected to drive GM% up P&T as 13-17% Projecting to continue to increase absolute dollar investments in Product % of Rev. & Tech at a decreasing rate Adj. As sales
Slide 15: Q&A
Q&A Rajeev Singh – Chief Executive Officer Steve Barnes – Chief Financial Officer Shantanu Nundy, MD – Chief Medical Officer
Slide 16: Appendix
Accolade Appendix
Slide 17: Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA
Reconciliations of Revenue to Adjusted Gross Profit & Net loss to Adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted to exclude interest expense (net), income tax expense (benefit), depreciation and amortization, stock-based compensation, and acquisit
Slide 18: Adjusted EBITDA GAAP to Non-GAAP Reconciliation
Adjusted EBITDA GAAP to Non-GAAP Reconciliation ($ in thousands) Fiscal year ended February 28 (29), 2018 2019 2020 2021 Net Income (Loss) $ (61,286) $ (56,496) $ (51,365) $ (50,652) Adjusted for: Interest expense, net 1,799 2,374 2,925 3,724) Income tax (benefit) -- 55 129 4 Depreciation and amorti
Slide 19: Accolade
Accolade PERSONALIZED HEALTHCARE